Trials / Completed
CompletedNCT03357315
Mix Vaccine for Metastatic Sarcoma Patients
Safety and Efficacy Study of Mix Vaccine in Sarcoma Patient
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of mix vaccine to small metastases of sarcoma.
Detailed description
By enrolling patients with small metastases of sarcoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of mix vaccine. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mix vaccine | Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle |
Timeline
- Start date
- 2017-11-30
- Primary completion
- 2018-11-30
- Completion
- 2019-08-30
- First posted
- 2017-11-29
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03357315. Inclusion in this directory is not an endorsement.